Physician profile
Amit Roy
NPI 1750813960
$3,753.08
in general payments reported to CMS, 2019-2025
29 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 86% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $876 · 2023: $795 · 2024: $834 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,877.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,375.09 | 2022-2025 | Optune, Optune Gio |
| Gt Medical Technologies, INC | $383.11 | 2022-2024 | Gammatile, Gammatile |
| Astrazeneca Pharmaceuticals LP | $314.55 | 2022-2025 | Imfinzi, Tagrisso, Enhertu |
| Regeneron Healthcare Solutions, INC. | $307.65 | 2022-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $196.13 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Tactile Systems Technology INC | $141.96 | 2025 | Nimbl, Flexitouch Plus |
| Novartis Pharmaceuticals Corporation | $130.88 | 2023-2025 | |
| Eisai INC. | $89.84 | 2023-2025 | |
| Seagen INC. | $84.98 | 2022-2023 | Tukysa, Padcev |
| Sumitomo Pharma America, INC. | $81.19 | 2023-2025 | Orgovyx |
| Reflexion Medical, INC. | $75.00 | 2022-2023 | Reflexion Medical Radiotherapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $70.03 | 2024-2025 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $52.81 | 2022-2025 | |
| Celgene Corporation | $49.21 | 2022-2023 | Pomalyst |
| Beigene USA, INC. | $46.11 | 2025 | Brukinsa, Tevimbra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $38.32 | 2023 | Prolaris |
| Boston Scientific Corporation | $37.80 | 2024-2025 | Spaceoar Vue System - 10ml |
| Amgen INC. | $36.60 | 2022 | |
| Emd Serono, INC. | $36.44 | 2023-2025 | Bavencio |
| Teleflex LLC | $34.49 | 2025 | Barrigel |
| Mevion_medical_systems_inc | $26.32 | 2022 | |
| Genzyme Corporation | $23.76 | 2022 | |
| Exelixis INC. | $22.38 | 2023 | Cabometyx |
| Beone Medicines USA, INC. | $17.63 | 2025 | Tevimbra |
| Janssen Biotech, INC. | $17.26 | 2025 | Talvey, Darzalex |
| Taiho Oncology, INC. | $16.79 | 2024 | |
| Palette Life Sciences, INC. | $16.35 | 2022 | |
| Incyte Corporation | $15.25 | 2025 | Pemazyre, Monjuvi |
| Daiichi Sankyo INC. | $15.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.